We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The HHS Office of Inspector General’s (OIG) assessment of state qui tam programs will be a hotly debated issue for observers
of a new law providing states with an increased share of Medicaid funds, industry sources say.
The HHS Office of Inspector General (OIG) is leading the federal government’s effort to limit off-label drug promotion — a move that will hurt public health protection and may violate the First Amendment, industry attorneys say.
The HHS Office of Inspector General’s (OIG) assessment of state qui tam programs will be a hotly debated issue for observers of a new law providing states with an increased share of Medicaid funds, industry sources say.
President Bush will soon name John Niederhuber the next director of the National Cancer Institute (NCI), taking the place of the nominee to run the FDA, Andrew von Eschenbach.
Inadequate FDA oversight of industry submissions and insufficient industry reporting has resulted in an inaccurate and incomplete National Drug Code Directory, the HHS Office of Inspector General (OIG) said.
HHS is excluding drugmakers from a new protection from the anti-kickback statute designed to promote adoption of electronic health records, arguing that these sectors cannot be trusted to abide by the law.
HHS is arguing that drug and devicemakers cannot be trusted to abide by the law and therefore cannot receive a new protection from the anti-kickback statute designed to promote adoption of electronic health records.
The HHS Secretary’s Advisory Committee on Human Research Protections (SACHRP) will seek legislation developing uniform human research protections in place of the current patchwork system, the group decided at an Aug. 1 meeting in Bethesda, Md.
HHS is excluding drug and devicemakers from a new protection from the anti-kickback statute designed to promote adoption of electronic health records, arguing that these sectors cannot be trusted to abide by the law.
Congress should legislate uniform human research protections in place of the current patchwork system, the Secretary’s Advisory Committee on Human Research Protections (SACHRP) decided at an Aug 1 meeting in Bethesda, Md.